164 related articles for article (PubMed ID: 8322282)
1. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.
Vicente V; Estellés A; Laso J; Moraleda JM; Rivera J; Aznar J
Thromb Res; 1993 Apr; 70(2):117-22. PubMed ID: 8322282
[TBL] [Abstract][Full Text] [Related]
2. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
Cattaneo M; Simoni L; Gringeri A; Mannucci PM
Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
[TBL] [Abstract][Full Text] [Related]
3. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
4. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.
Casonato A; Sartori MT; Pontara E; Zucchetto A; Dannhäuser D; Patrassi G; Girolami A
Blood Coagul Fibrinolysis; 1992 Apr; 3(2):149-53. PubMed ID: 1606286
[TBL] [Abstract][Full Text] [Related]
5. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
Patrassi GM; Sartori MT; Casonato A; Viero ML; Pontara E; Saggiorato G; Girolami A
Thromb Res; 1992 Jun; 66(5):517-26. PubMed ID: 1523608
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm.
Wall U; Jern S; Tengborn L; Jern C
Blood; 1998 Jan; 91(2):529-37. PubMed ID: 9427706
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
9. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
Greer IA; McLaren M; Belch JJ; Lowe GD; Forbes CD
Haemostasis; 1986; 16(1):15-9. PubMed ID: 3084364
[TBL] [Abstract][Full Text] [Related]
10. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
11. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
Wieczorek I; Ludlam CA; MacGregor IR
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
[TBL] [Abstract][Full Text] [Related]
12. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
Kaufmann JE; Vischer UM
J Thromb Haemost; 2003 Apr; 1(4):682-9. PubMed ID: 12871401
[TBL] [Abstract][Full Text] [Related]
13. The role of the spleen in regulating the plasma levels of factor VIII--von Willebrand's factor after DDAVP.
Garcia VV; Coppola R; Mannucci PM
Blood; 1982 Dec; 60(6):1402-6. PubMed ID: 6814552
[TBL] [Abstract][Full Text] [Related]
14. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.
Trummer A; Haarmeijer B; Werwitzke S; Wermes C; Ganser A; Budde U; Tiede A
Haemophilia; 2013 Mar; 19(2):236-41. PubMed ID: 23051555
[TBL] [Abstract][Full Text] [Related]
15. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
Arshad F; Stoof SC; Leebeek FW; Ruitenbeek K; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Kruip MJ; Lisman T
Liver Int; 2015 Jul; 35(7):1809-15. PubMed ID: 25522671
[TBL] [Abstract][Full Text] [Related]
16. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
[TBL] [Abstract][Full Text] [Related]
17. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
18. DDAVP induces systemic release of urokinase-type plasminogen activator.
Levi M; ten Cate JW; Dooijewaard G; Sturk A; Brommer EJ; Agnelli G
Thromb Haemost; 1989 Sep; 62(2):686-9. PubMed ID: 2510348
[TBL] [Abstract][Full Text] [Related]
19. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL
Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673
[TBL] [Abstract][Full Text] [Related]
20. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
Moffat EH; Giddings JC; Bloom AL
Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
